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Abstract
Purpose Tumor progression is associated with cell migration,
invasion and metastasis. These processes are accompanied by
the activation of specific proteases that are either linked to
cellular membranes or are secreted into extracellular spaces.
TNF-α is known to play an important role in various aspects
of tumor progression. The aim of this work was to assess the
effect of TNF-α on the migration of breast cancer cells and, in
addition, to assess its associationwith the location ofmembrane-
associated proteases in lipid rafts.
Methods Wound scratch healing and Transwell migration as-
says were used to study the effect of TNF-α on the migration
of both hormone-dependent and hormone-independent breast
cancer-derived cells, i.e., MCF7 and MDA-MB-231, respec-
tively. The expression and secretion of three matrix
metalloproteases, MMP9, MMP2 and MT1-MMP, and two
dipeptidyl peptidases, CD26 and FAP-α, was investigated
using RT-PCR, Western blotting and gelatin zymography. In
addition, activation of the MAPK/ERK signaling pathway
was investigated by Western blotting.
Results We found that a TNF-α-induced enhancement of
breast cancer cell migration was accompanied by an increased
secretion of MMP9, but not MMP2, into the culture media.
We also found that TNF-α upregulated the expression of the
dipeptidyl peptidases CD26 and FAP-α in a dose-dependent
manner and, in addition, enhanced the concentration of all five
proteases in lipid rafts in the breast cancer-derived cells tested,
regardless of cell type. Furthermore, we found that TNF-α
activated the MAPK/ERK signaling pathway by increasing
the ERK1/2 phosphorylation level. Application of the MEK/
ERK1/2 inhibitor U-0126 resulted in down-regulation of
TNF-α-induced MMP9 secretion and abrogation of the en-
hanced concentration of proteases in the lipid rafts.
Conclusions From our results we conclude that TNF-α-
induced activation of the MAPK/ERK signaling pathway
may promote breast cancer cell migration via both upregula-
tion of MMP9, CD26 and FAP-α and concentration of these
proteases, as also MT1-MMP and MMP2, in the lipid rafts.
TNF-α may serve as a potential therapeutic target in breast
cancers susceptible to TNF-α stimulation.
Keywords TNF-α . DPPIV/CD26 . FAP-α/F19/seprase .
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1 Introduction
Caner progression depends on various cellular events, includ-
ing cytokine-dependent promotion of cell migration and the
production and activation of different proteolytic enzyme sys-
tems. A major step in invasion and metastasis is the destruc-
tion of a dense network of structural proteins that act as a
natural barrier. This process is associated with the activation
of specific proteases that are either linked to cellular mem-
branes or are secreted into extracellular spaces [1]. Proteases
are crucial players, not only in the degradation of extracellular
matrix (ECM) components, but also in the processing of di-
verse soluble bioactive mediators and the shedding of a large
variety of cell surface proteins. The production of proteases
is tightly regulated by various signals mediated by cytokines,
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growth factors and mechanical stress [1, 2]. Many cells in-
crease their proteolytic activity in response to inflammatory
cytokines, such as tumor necrosis factor α (TNF-α), which is
frequently upregulated in human epithelial malignancies such
as breast cancer [3–5]. TNF-α exerts diverse functions in the
biology of cancer. In addition to causing cell death, it can
stimulate cancer cell survival and proliferation as well as pro-
mote angiogenesis, tumor cell migration and invasion [6].
The role of matrix metalloproteinases (MMPs) and dipeptidyl
peptidases (DPPs) in invasive and metastatic processes has am-
ply been documented [1, 7–9]. MMPs are zinc- and calcium-
dependent peptidases essential for ECM reorganization. As such,
they can determine the aggressiveness/invasiveness of cancer
cells. Membrane-type metalloproteinase 1 (MT1-MMP, also
known as MMP14) is a member of a membrane-anchored
MMP subfamily [10]. It is synthesized as a 64-kDa pro-enzyme
that undergoes furin-catalyzed proteolytic cleavage resulting in
an active 54-kDa protein. This protein cannot only degrade ECM
fibrillar components, proteoglycans or cell surface receptors and
cell adhesion molecules, but can also act as a specific initiator of
zymogen ac t iva t ion of o the r MMPs, inc lud ing
metalloproteinase-2 (MMP2/gelatinase A) and, indirectly,
metalloproteinase-9 (MMP9/gelatinase B) [2, 11, 12]. MMP2
and MMP9, two members of the gelatinase subfamily of
MMPs, are thought to particularly play a role in the early steps
of cancer cell invasion and tumor vascularization since they
cleave type IV collagen, laminin and elastin, which are the major
components of the basement membrane (BM). Similar to all
other solubleMMPs,MMP2 andMMP9 are secreted as inactive
pro-enzymes. Their latent forms can be activated through an
autocatalytic reaction or through cleavage by other proteases,
including serine proteases. In addition to their ability to directly
degrade extracellular components, MMP2 and MMP9 are
known to affect cell signaling by releasing the active ectodomain
of the fibroblast growth factor receptor 1 (FGFR-1) or by acti-
vating transforming growth factor β1 (TGF-β1). MMP2 and
MMP9 are secreted into the extracellular space, but they can also
become localized at the surface of tumor cells. By doing so, they
are able to associate with the MT1-MMP/TIMP-2 complex,
αvβ3 andα3β1 integrins, and/or CD44 and, as such, to degrade
the local ECM, which enhances the invasive capacity of cancer
cells [2, 7, 8, 13].
CD26 (dipeptidyl peptidase IV, DPPIV) and fibroblast ac-
tivation protein-α (FAP-α, or F19 cell surface antigen, also
known as seprase) are two members of the family of DPPs,
i.e., serine proteases exhibiting a post-proline dipeptidyl ami-
nopeptidase activity. In their active constitutions, both en-
zymes form transmembrane homo- or hetero-dimeric glyco-
protein complexes with a molecular weight of ~200 kDa. The
FAP-α and DPPIV genes are located close together on chro-
mosome 2 (q23 and q24.3, respectively). The encoded proteins
share 52% amino acid sequence identity, but they differ in their
cellular and substrate specificity. CD26 is a ubiquitously
expressed peptidase that releases a number of biologically ac-
tive peptides involved in cellular growth, migration, invasion,
neovascularization and immune system activation. FAP-α
cleaves larger proteins and shows a collagen type I-specific
gelatinase activity. FAP-α is selectively expressed by
myofibroblast-like cells within the tumor stroma, by fibrotic
and granulation tissue cells and by several types of cancer cells.
MT1-MMP and both gelatinases, as well as CD26 and FAP-α,
have been found to localize to sites of focal ECM degradation,
i.e., in specialized F-actin-basedmembrane protrusions denoted
as invadopodia or cell-matrix adhesive structures enriched in
ordered membranous micro-domains known as lipid rafts
[14–16].
Lipid rafts are more tightly packed than its surrounding non-
raft lipid bilayer and they can sequester specific proteins involved
in cell-cell interactions, actin cytoskeleton organization, cell-
ECM adhesion and membrane dynamics. As such, they can
serve as platforms for membrane trafficking, signaling and po-
larization. Lipid rafts organizemany signaling proteins, including
integrin and non-integrin receptors, and various enzymes such as
kinases, phosphatases or membrane-associated proteases to reg-
ulate themotility of cells. The localization of these proteins inside
or outside the lipid rafts determines their functional activities.
Lipid rafts are tightly linked to the targeted delivery, organization
and activation of specialized molecules implicated in cancer me-
tastasis at the leading edge of migrating cells [16–21]. Lipid rafts
have been shown to be crucial for the formation and extension of
membrane protrusions, and lipid raft-disrupting reagents have
been found to decrease the migratory potential of tumor cells
[22, 23].
It is still unclear, however, whether a cytokine-dependent
increase of cancer cell migration and invasion is related to
enhanced ECM-degrading activities via the accumulation of
proteolytic enzymes in lipid rafts. To address this issue we
stimulated estrogen-dependent MCF7 breast cancer-derived
cells and highly invasive, hormone-independent MDA-MB-
231 breast cancer-derived cells with TNF-α and subse-
quently assessed changes in cell migration in conjunction
with the levels of two dipeptidyl peptidases, FAP-α and
CD26, and three metalloproteases, MT1-MMP, MMP2 and
MMP9. Additionally, we assessed the effect of TNF-α on
alterations in the concentrations of all these proteases in
detergent resistant membranes (DRMs) with emphasis on
the role of the MAPK/ERK signaling pathway in this
process.
2 Materials and methods
2.1 Cell culture
MDA-MB-231 and MCF7 breast cancer-derived cells were
cultured in DMEM (Lonza, Verviers, France), supplemented
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with 10 % fetal bovine serum (FBS) (Lonza), 1 % glutamine,
100 U/ml penicillin and 100 mg/ml streptomycin at 37 °C in a
5 % CO2 humidified incubator. The cells were seeded in 12-
well plates or 10 cm Petri dishes and maintained until they
reached 70–90 % confluency. Next, the cells were starved
overnight in serum-free DMEM and subsequently stimulated
with 10 ng/ml TNF-α for 24 h. No TNF-α was added to the
control. Conditioned medium (CM) was collected for sub-
strate zymography. The cells were lysed for both total RNA
and protein extractions (see below).
2.2 Reagents and antibodies
TNF-α was obtained from ProSpec-Tany TechnoGene Ltd.
(cyt-223-b) and U0126 was purchased from Santa Cruz
(CAS 109511–58-2). The antibodies used were: rabbit anti-
phospho-ERK1/2 (T202/Y204, Cell Signaling), mouse anti-
ERK1/2 (L34F12, Cell Signaling), rabbit anti-MMP-9
(AB19016, Merck Mil l ipore) , rabbi t ant i -MMP2
(VARP20016_T100, Aviva), rabbit anti-MMP14 (PA5–13,
183, Thermo Scientific), rabbit anti-FAP-α (GTX102732,
GeneTex), goat anti-DPPIV/CD26 (AF1180, R&D
Systems), rabbit-anti-Cortactin (H-191) (sc-11,408, Santa
Cruz Biotechnology, Inc.), goat anti-actin (I-19) (sc-1616,
Santa Cruz Biotechnology, Inc.) and mouse anti-FL-2 (B6)
(sc-28,320, Santa Cruz Biotechnology, Inc.). The cholera tox-
in subunit B-HRP conjugate was obtained from Molecular
Probes (C-34,780). Millicell Hanging Cell Culture Inserts
(8.0 μm) were purchased from Merck Mil l ipore
(PIEP15R48) and blotting membranes were purchased from
Bio-Rad (162–0094). Immuno-detectionwas performed using
HRP-conjugated donkey anti-rabbit (sc-2313), donkey anti-
goat (sc-2020) and goat anti-mouse (sc-2005) antibodies pur-
chased from Santa Cruz Biotechnology, Inc. and
Pierce™ECL Western Blotting Substrate (32,106, Thermo
Scientific).
2.3 Semi-quantitative reverse transcription polymerase
chain reaction (RT-PCR)
Total RNA isolation was performed using a RNeasy kit
(Qiagen, USA). All the RT-PCR reactions were performed
using a one-step RT-PCR kit (Clontech Laboratories, Inc., A
Takara Bio Company), according to the manual provided by
the manufacturer. For RT-PCR, 1 μl of the total RNA extract-
ed from each sample was added to a 20 μl final reaction
volume of RT-PCRmix containing 0.25 pmol of each specific
primer. Reverse transcription (RT) was performed for 1 h at
50 °C and 5 min at 94 °C. To amplify the FAP-α transcripts,
we used primer pair 5′-GCTGGAGCTAAGAATCCCGTT
GTT CG-3′ (sense) and 5′-TGC TTG GAG GAT AGC TTC
CAATGC T-3′ (antisense). The FAP-α amplification product
length was 544 bp. The PCR conditions were 30 s at 94 °C,
45 s at 60 °C and 1 min at 68 °C (30 cycles). To detect
genomic DNA contamination, RT-free PCR controls were in-
cluded. To amplify the CD26 (473 bp) and MMP-14 (395 bp)
transcripts we used the primer pairs 5′- GGAAGATGGAAC
TGC TTA GTG GCA CG -3′ (sense) and 5′- TCT CAG CCC
TTT ATC ATT CAC GCT GC -3′ (antisense), and 5′-TCA
TGA TCT TCT TTG CCG AGG GCT-3′ (sense) and 5′-
TTT ATC AGG AAC AGA AGG CCG GGA-3′ (antisense),
respectively. The PCR products were separated and visualized
in 1 % agarose gels containing ethidium bromide, digitized,
and assessed for densitometry using ImageJ software. For
semi-quantitative analyses the transcripts were related to co-
amplified actin, a housekeeping control transcript. The actin
primers used were 5′-TAC AAT GAG CTG CGT GTG GCT
CCC CCC G-3′ (sense) and 5′-AAT GGT GAT GAC CTG
GCC GTC AGG C-3′ (antisense) applied under the same am-
plification conditions as described above, yielding a 479 bp
product. The pixel density of each individual PCR product
was calculated relative to the pixel densities of the actin tran-
scripts, the values of which were set at 1.
2.4 Isolation of DRM and DSM membrane fractions
For membrane micro-domain fractionation, 15 x 106 cells
were lysed for 30 min on ice in 1 % Triton X-100 in TNE
buffer (150 mM NaCl, 1 mM EDTA, 25 mM Tris, pH 7.4)
containing a protease inhibitor cocktail and ultra-centrifuged
on a discontinuous 5 %/30 %/40 % sucrose gradient. To this
end, the cell lysates were mixed 1:1 with 85% sucrose in TNE
buffer containing 1 % Triton X-100. This mixture (1 ml) was
placed in the bottom of a 4.5 ml centrifuge tube. Next, 2.7 ml
of 30 % sucrose was poured on the top of the diluted lysate
and subsequently overlaid with 0.8 ml of 5 % sucrose in TNE
buffer. The samples were centrifuged in a Ti60 rotor
(Beckman) at 35,000 RPM at 4 °C for 16 h. Eight 550 μl
sucrose gradient fractions were collected from the top to the
bottom of the tube and assessed for GM1 ganglioside and total
protein content by dot blotting using a peroxidase-linked chol-
era toxin B subunit (CTX-HRP) and Ponceau S, and for
flotilin-2 by immunoblotting. Low-density fractions contain-
ing detergent resistant membranes (DRM) are known to be
enriched in GM1 and flotilin-2 in contrast to high-density
fractions, which contain detergent soluble membranes
(DSM) and have a notably lower concentration of both of
these factors.
2.5 SDS-PAGE and Western blotting
For SDS-PAGE, proteins in each fraction (see above) were
precipitated with 10 % trichloroacetic acid (TCA), washed
twice with cold acetone and suspended in 50 μl (4×)
Laemmli sample buffer. All the samples were heated at
95 °C for 10 min and electrophoresed (10 μl/slot) through
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10 % SDS polyacrylamide gels. After electrophoresis, the
samples were transferred overnight at 95 mA to nitrocellulose
membranes. These membranes were subsequently blocked for
1 h with 5 % non-fat milk in PBS (pH 7.4) at room tempera-
ture and then incubated overnight at 4 °C with primary anti-
bodies. Semi-quantitative digital image analyses were per-
formed using ImageJ software to detect the integrated inten-
sities of particular bands. The results are expressed as ratios of
integrated density values of corresponding protein bands from
treated to untreated control cells.
2.6 Gelatin zymography
For the analysis of gelatinolytic activity, sucrose gradient frac-
tions as well as conditioned media were mixed 1:0.5 v/v with
sample buffer (62.5 mMTris-HCl, pH 6.8, with 10% glycerol,
2 % SDS and 0.05 % bromophenol blue). A total of 30 μl of
each of the non-reduced samples was loaded in 10 % SDS-
polyacrylamide gels copolymerized with gelatin (2 mg/ml).
After semi-native electrophoresis, the enzymes were renatured
by washing out the SDS twice in 50 mM Tris-HCl (pH 7.5)
with 2.5 % Triton X-100 for 30 min at room temperature.
Next, the gels were incubated for 20 h at 37 °C in 50 mM
Tris-HCl (pH 7.5) containing 150 mM NaCl, 10 mM CaCl2,
1 μM ZnCl2 and 0.05 % Brij-35, stained with 0.12 %
Coomassie blue and de-stained with a solution containing
5 % acetic acid and 10 % ethanol in water.
2.7 Transwell migration assay
2.5 x 104 MDA-MB-231 and MCF7 cells suspended in 1 ml
serum-free medium were loaded onto a upper 8 μm pore size
chamber inserted in a 12-well cell culture plate. The lower
chamber was filled with DMEM supplemented with 1 %
FBS as a chemoattractant. The cells were allowed to adhere
before being treated with 10 ng/ml TNF-α and then incubated
for 24 h at 37 °C in 5 % CO2. After this incubation, the inserts
were removed and the remaining non-migrating cells on the
upper surface of the membrane were removed with a cotton
swab. The cells that migrated to the lower surface of the mem-
brane were fixed with 5 % paraformaldehyde (PFA) in PBS
for 20 min at room temperature, washed with PBS and then
treated with 0.5% Triton X-100 for 5 min. Next, the cells were
stained with DAPI solution (Mounting Medium with DAPI,
Sigma-Aldrich) and examined using a Zeiss LSM 510meta
microscope at 20× magnification (Plan Apochromat 20×/0,
8). Pictures of five randomly chosen fields were taken and
migrating cells were counted using ImageJ software. The av-
erage number of migrating cells for each condition was calcu-
lated and differences in the numbers of cells that migrated
through the membrane were calculated.
2.8 Wound healing assay
MDA-MB-231 and MCF7 cells were seeded in Petri dishes
and cultured to reach 90 % confluency in complete medium.
Next, the cells were starved overnight and a sterile 200 μl
pipet tip was used to scrape four wounds through the cell
monolayer. The cells were gently rinsed before being treated
with 10 ng/ml TNF-α. Pictures were taken immediately be-
fore TNF-α application and after 24 h using phase contrast
optics. Images were acquired with a 10×/1.25 numerical aper-
ture objective on an inverted microscope (Zeiss) equipped
with a digital camera using Image-Pro Plus version 5.1.2.59.
Wound areas were quantified using imageJ software version
1.43u. The results are presented as wound closure rates.
3 Results
3.1 TNF-α affects MMP9 protein level and secretion
in breast cancer-derived cells
To examine the effect of TNF-α on gelatinase production and
secretion, we treated MDA-MB-231 and MCF7 cells with
TNF-α at the indicated concentrations for 24 h in serum-free
media. A dose-dependent increase in theMMP9 concentration
in conditioned media and in cell lysates was observed. A
strong cellular response was seen in the TNF-α concentration
range of 10–100 ng/ml (Fig. 1a). In case of MMP2, non-
significant changes in protein level after TNF-α treatment
were observed in cell lysates by Western blotting as well as
in conditioned media by gelatin zymography (Fig. 1a-b).
3.2 TNF-α affects breast cancer-derived cell migration
Using a wound healing assay and a Transwell cell migration
assay we found that TNF-α enhanced the migration of both
MDA-MB-231 and MCF-7 cells. As shown in Fig. 2a the
efficiency of the wound closure was significantly lower in
the untreated control cells compared to the TNF-α stimulated
cells. We found that TNF-α at a concentration of 10 ng/ml
enhanced wound closure by ∼6 % and ~9 % at 24 h compared
to the control (untreated) MDA-MB-231 and MCF-7 cells,
respectively. This enhanced migration after TNF-α treatment
was confirmed by an independent Transwell assay in which
the number of cells that migrated across 8 μm diameter pores
over 24 h was counted. The data of the Transwell assay are
depicted in Fig. 2b.
3.3 TNF-α affects CD26, FAP-α and MT1-MMP
expression
Initially, we set out to compare the CD26, FAP-α and MT1-
MMP mRNA expression levels in cells treated with 10 ng/ml
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TNF-α for 24 h with those in untreated cells by RT-PCR.
Although the mRNA transcript levels of all these genes were
found to increase in cells stimulated with TNF-α compared to
unstimulated control cells (Fig. 3a), we found that TNF-α had
only a slight impact on the expression of FAP-α and
MT1-MMP. Similar effects were observed in both the
MDA-MB-231 and the MCF-7 cells. These findings were
confirmed by examining the respective protein levels by
Western blotting. By analyzing the pixel intensities of the
protein bands normalized to actin, we found that all three
proteins were upregulated in a dose-dependent manner (Fig.
3b). Substantial changes were, however, only observed for
CD26. Statistically significant increases in FAP-α protein
levels were also observed, but only in cells exposed to the
higher concentrations of TNF-α (20–100 ng/ml).
3.4 TNF-α induces localization of membrane-associated
proteases into lipid rafts
Sucrose gradient fractions were analyzed by Western blotting
for flotillin-2 content and by dot blotting, using a peroxidase-
linked cholera toxin B subunit, for GM1 content to identify
DRM fractions that contain lipid raft material. The highest
concentrations of flotillin-2 and GM1 were found in fraction
2. Therefore, we here refer to fraction 2 as a DRM fraction and
to fraction 7, which is low in DRM markers, as a DSM frac-
tion (Fig. 4a).
To determine whether membrane-associated proteases are
localized into lipid rafts under TNF-α stimulation we deter-
mined the levels of FAP-α, CD26, MT1-MMP in DRM frac-
tions, isolated fromMDA-MB-231 and MCF7 cells untreated
Fig. 1 TNF-α induces increases inMMP9, but notMMP2, synthesis and
activity in breast cancer cells. a MDA-MB-231 and MCF7 cells were
cultured in the presence of TNF-α at the indicated concentrations for
24 h. Conditioned media were collected and subjected to analysis of
secreted gelatinases by gelatin zymography. Electrophoretic bands were
quantified by densitometry and normalized to the untreated controls. Bar
graphs present the relative fold change in MMP9 and MMP2 activity in
relation to TNF-α concentration. b Total cell lysates were prepared from
untreated or TNF-α treated cells for 24 h at the concentration indicated
and immunoblotted using anti-MMP9 and anti-MMP2 antibodies.
Protein bands were quantified by densitometry and normalized to the
corresponding actin (housekeeping protein) band. Bar graphs present
the relative fold change in protein level for MMP9 and MMP2. All data
are presented as mean ± SEM from at least three independent experiments
(n ≥ 3). *P < 0.05, **p < 0.005, ***p < 0.0001 compared to control
(untreated) cells
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and treated with 10 ng/ml TNF-α for 24 h, by Western blot-
ting. In Fig. 4b the distribution is shown of three transmem-
brane proteases, FAP-α, CD26 and MT1-MMP, in total cell
lysates and in the low-density (DRM) as well as high-density
(DSM) fractions derived from cells treated with TNF-α or
untreated control cells. We found increased levels of all these
proteins in the DRM fractions of treated cells as compared to
those of untreated control cells (both cell types). In the DRM
fractions of the TNF-α treated cells increased levels of MMP9
and MMP2 were also observed by gelatin zymography and
Western blotting. As shown in Fig. 4c, only active forms of
gelatinases were localized in the DRM.
To confirm that the TNF-α-induced changes observed in
the localization of proteases in the lipid rafts are related to cell
migration, we assessed the levels of actin and cortactin in the
sucrose gradient fractions from treated and untreated (control)
cells. These two proteins are known to be tightly associated
with the formation of invadopodia, membrane protrusions that
are characteristic for highly invasive cancer cells. Indeed, we
found that also the concentrations of actin and cortactin
increased in the DRM fractions of MDA-MB-231 and
MCF7 cells treated with TNF-α (Fig. 4d).
3.5 U-0126 affects TNF-α-induced localization
of proteases in lipid rafts through the MAPK/ERK
pathway
Through Western blot analyses of MDA-MB-231 cell lysates
we observed a substantial increase in ERK1/2 phosphoryla-
tion after TNF-α treatment (Fig. 5a). U-0126 is known to
selectively block the activity of the MAP kinase MEK, which
is an activator of the ERK1/2 kinases. After pretreatment of
MDA-MB-231 cells with U-0126 (10 μM) we observed an
abrogation TNFα- induced MMP9 secretion in conditioned
media (Fig. 5b). Western blot analyses of MMP9 in DRM
fractions from cells pretreated with U-0126 and treated with
TNF-α revealed that inhibition of the MAPK/ERK pathway
blocks the TNF-α-induced increases in protease concentra-
tions in the DRM fractions (Fig. 5c). Similar results were
Fig. 2 Effect of TNF-α on cell
migration. a Cell migration
evaluated by scratch wound
healing assay. Cells were treated
with TNF-α or left untreated
(control). Images were taken at 0
and 24 h after wound formation,
and the wound surface areas were
measured using Image J software
and normalized to the initial state.
Representative phase-contrast
images of MDA-MB-231 and
MCF-7 cells migrating into the
wounded area are shown (left).
Bar graphs present relative
changes in wound closure for
cells treated and untreated with
TNF-α. b Cell migration
evaluated by transwell migration
assay. Representative images of
migrating cells on the bottom of
Millicell’s membranes (pore size
8 μm) in the presence (right pan-
el) and in the absence of TNF-α
after 24-h incubation are shown.
Bar graphs represent number of
transmigrating cells in TNF-α
treated and untreated cell cultures.
All data are presented as
mean ± SEM from three
independent experiments (n = 3).
*P < 0.05, **p < 0.005
***p < 0.0001 compared to
control (untreated) cells
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obtained for MT1-MMP, the protease of which the total levels
were not significantly changed after TNF-α treatment.
4 Discussion
Tumor necrosis factor α (TNF-α) is a key cytokine that is
involved in the generation of inflammatory responses.
Although TNF-α was initially found to induce cell death in
some cancer types, recent studies have shown that it may also
exert tumor-promoting activities such as the induction of
transformation, proliferation, angiogenesis, invasion and me-
tastasis [6]. A high level of TNF-α is a characteristic of many
malignant cancers, including breast cancers, and has frequent-
ly been associated with an aggressive behavior and a poor
prognosis [3]. TNF-α is primarily produced by macrophages,
but it can also be produced by a variety of other stromal cells,
as well as cancer cells themselves. Thus, it may act in both a
paracrine and an autocrine manner [24]. TNF-α is
known to play a particular role in enhancing tumor cell
migration and invasion, but the underlying mechanisms are
still elusive [4, 24].
Here, different in vitro assays were employed to assess the
effect of TNF-α on breast cancer cell migration.We found that
TNF-α strongly promoted the migration of both hormone-
dependent and highly invasive, triple-negative, breast cancer
cells using a Transwell assay and to accelerate wound closure
using a scratch assay. These results are in keeping with studies
reporting the pro-migratory activity of TNF-α on melanoma
cells, bladder cancer cells, cervical cancer cells and leukemia
Fig. 3 Effect of TNF-α on CD26, FAP-α and MT1-MMP protein and
mRNA expression levels. a MDA-MB-231 and MCF7 cells were
stimulated with TNF-α (10 ng/ml) or left unstimulated for 24 h after
which total RNAwas isolated. Levels of CD26, FAP-α and MT1-MMP
transcripts were analyzed by RT-PCR using gene-specific primers
followed by agarose gel electrophoresis. Electrophoretic bands were
quantified by densitometry and normalized to the housekeeping gene
included (actin). Bar graphs present relative fold changes in gene
expression for CD26, FAP-α, and MT1-MMP in both cell lines. b Total
cell lysates were prepared from untreated or TNF-α treated cells for 24 h
at the concentration indicated and immunoblotted using anti-CD26, anti-
FAP-α and anti-MT1-MMP antibodies. All protein bands were quantified
by densitometry and normalized to the corresponding actin
(housekeeping protein) band. Bar graphs represent the fold changes in
protein levels for CD26, FAP-α and MT1-MMP in relation to TNF-α
concentration. All data are presented as mean ± SEM from at least three
independent experiments (n ≥ 3). *P < 0.05 compared to control
(untreated) cells
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cells [4, 25–27]. In our current study, TNF-α-induced cell
migration was accompanied by an increased secretion of
MMP9, but not MMP2, into the culture media. MMP2 is
known to be expressed at a constant level by various cell
types, while the synthesis and secretion of MMP9 is known
to be tightly regulated by different biological factors [8, 27].
TNF-α is considered to be one of the strongest physiological
inducers of MMP9 expression, the enzyme which appears
necessary for sustained migration of various cell types, includ-
ing cancer cells [28–30]. MMP9 was found by others to be
implicated in promoting breast cancer cell migration and in-
vasion through interactions with integrins and non-integrin
type receptors such as CD44 [31]. Using MMP9 knockout
mice, it was found that MMP9 is essential for the migration
of smooth muscle and immune cells, and that disruption of
MMP9-cell surface interactions can cause a dramatic decrease
in cell movement and tumor invasiveness [32, 33].
Here, we found that also one of dipeptidyl peptidases,
CD26, becomes significantly upregulated in response to
TNF-α. In parallel, we observed a markedly increased uptake
of all studied proteases into lipid rafts after TNF-α treatment,
regardless whether TNF-α-induced changes in mRNA or
protein levels were relatively high or onlyminor, as in the case
of MT1-MMP.
Recently, it was postulated that lipid rafts may play a crit-
ical role in cancer cell adhesion and migration [18, 34]. Lipid
rafts, which are cholesterol- and sphingolipid-rich membranes
resistant to non-ionic detergents, appear to be directly associ-
ated with various cellular adhesion structures such as focal
contacts and invadopodia and, thereby, essential for cell-
ECM interactions and matrix degradation. Membrane rafts
have been described in numerous malignant cancer models,
including breast cancer models, as being highly ordered mem-
branous domains determining the activation of cell survival
signaling pathways. These domains were also found to be the
basis for resistance to targeted cancer therapy and, according-
ly, disruption of the membrane raft structure has been found to
decrease this resistance in cancer cells [18]. Lipid rafts have
been found to be concentrated at the leading edge of
invadopodia in different types of breast cancer cells, and direct
manipulation of cholesterol levels with methyl-β cyclodextrin
(MβCD) or statins was found to impair focal adhesion disas-
sembly as well as invadopodia formation and their functions
[18, 21, 34, 35]. Invadopodia are specialized F-actin and
Fig. 4 TNF-α-induced accumulation of membrane-associated proteases
in lipid rafts. aDiscontinuous sucrose density gradient ultracentrifugation
was used to isolate detergent resistant membranes (DRM) and detergent
soluble membranes (DSM) from TNF-α treated or untreated MDA-MB-
231 and MCF7 cells at 10 ng/ml for 24 h. Fractions (1–8) were collected
from the top of the gradient and the distribution of the lipid raft markers,
glycosphingolipid (GM1) and Flotillin 2 (FL2), was determined by dot
blotting and Western blotting using HRP-conjugated cholera toxin
(middle panel) and a specific antibody directed against Flotillin 2 (FL2)
(bottom panel). Total proteins in sucrose gradient fractions were visual-
ized by Ponceau-S (PS) staining (top panel). b Visualization of
membrane-associated proteases in cell lysates as well as in DRM and
DSM fractions derived from TNF-α treated cells and untreated control
cells by immunoblotting. TNF-α stimulation of MDA-MB-231 and
MCF7 cells induces increases in CD26 (fold change: 8.01 and 1.26),
FAP-α (fold change: 1.68 and 2.03) and MT1-MMP (fold change: 3.84
and 25.47) concentrations, respectively in the DRM fraction.c
Distribution of MMP9 and MMP2 to DRM and DSM fractions in the
presence or absence of TNF-α was analyzed by gelatin zymography and
Western blotting. Both gelatinases are slightly increased (fold change:
1.23 and 1.37 for MMP9 and MMP2, respectively) in the DRM fraction
after TNF-α induction. d Changes in the concentration of the
invadopodia-associated proteins actin and cortactin in DRM fractions in
cells treated with TNF-α were observed by immunoblotting. The fold
changes in protein levels for cortactin and actin are 2.02 and 24.87,
respectively. No differences in the total levels of these proteins under
TNF-α stimulation (cell lysate panel) were observed
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cortactin-rich membrane protrusions formed at the ventral sur-
face of highly aggressive cancer cells, including MDA-MB-
231, and display local proteolytic activity towards extracellu-
lar matrix constituents. Their high lytic activity seems to be
due to the accumulation of proteolytic enzymes at the sites of
active actin polymerization [34–36]. A number of key
invadopodial components, including proteolytic enzymes
such as MT1-MMP and CD26, have been found to reside in
lipid rafts [18, 21, 37–39].
Here, we found that exogenous TNF-α enhances the accu-
mulation of both MT1-MMP and CD26 and, additionally,
FAP-α in lipid rafts in different breast cancer-derived cells.
Moreover, we found that lipid rafts of TNF-α-treated cells
were also enriched in two gelatinases, MMP9 and MMP2.
MMP2 and MMP9 are secretory proteins, but small amounts
of the enzymes have consistently been found on the surface of
various cells, including breast cancer cells [21, 40]. In contrast
to the DSM fractions in which both pro-enzymes and active
forms of MMP9 and MMP2 were identified, we only found
active enzymes in the DRM fractions, regardless whether
TNF-α was added to the culture media or not. This finding
suggests a contribution of lipid rafts in the activation of
membrane-associated gelatinases. Since cancer cell migration
and invasiveness are thought to correlate with the presence of
actin- and cortactin-based protrusions, we next set out to as-
sess changes in the accumulation of both these proteins in
lipid rafts of breast cancer-derived cells stimulated with
TNF-α to establish a potential contribution of invadopodia
in TNF-α-induced cell migration. Recently, TNF-α was
shown to promote invadopodia formation in MDA-MB-231
cells [41]. Here, we found that the concentrations of actin and
cortactin were altered in lipid rafts of TNF-α stimulated cells.
However, in the case of cortactin, only a shortened form of the
protein, corresponding to cortactin splice variant 1 (SV1),
could be detected in the DRM fraction.
A number of different growth factors and cytokines, in-
cluding TNF-α, have been found to regulate MMP9 expres-
sion via the extracellular signal-regulated kinase (ERK) [26,
42, 43]. It was previously found that granulocyte colony stim-
ulating factor (G-CSF) is able to increase MT1-MMP gene
expression and protein synthesis in hematopoietic cells and
to promote partitioning of MT1-MMP into lipid rafts through
a mechanism that is regulated by the phosphatidylinositol 3-
kinase (PI3K) signaling pathway [39]. Here, we showed that
the TNF-α-enhanced location of proteases in lipid rafts is
dependent on ERK signaling pathway activation. We also
showed that the application of U-0126, a specific MEK/
ERK inhibitor, led to an effective block of the TNF-α-
induced accumulation ofMMP9 andMT1-MMP in lipid rafts.
Since we found that TNF-α has only a minor effect on MT1-
MMP mRNA and protein expression levels, its role in the
enhancement of protease uptake into lipid rafts seems to be
independent of its role as an inducer of protease gene
expression.
Taken together, we conclude that TNF-α-induced enhance-
ment of breast cancer cell migration is accompanied by
Fig. 5 TNF-α stimulation of MDA-MB-231 cells increases
accumulation of proteases in lipid rafts through the MAPK/ERK
pathway. a MAPK/ERK activation was assayed by immunoblotting for
phospho-ERK1/2 (pERK1/2 panel) in cells treated with TNF-α (10 ng/
ml) for the indicated times. Blots were stripped and re-probed for total
ERK1/2 (ERK1/2 panel). bMDA-MB-231 cells were either left untreated
or pretreated with the MEK/ERK inhibitor, U-0126 (10 μM), for 1 h.
Next, the cells were stimulated with TNF-α (10 ng/ml) for 24 h. Levels
of secreted MMP9 in the culture media were assayed by gelatin
zymography (top panel) and the levels of MT1-MMP in cell lysates were
analyzed byWestern blotting (middle panel). Actin was used as a loading
control (bottom panel). c The concentration of MMP9 and MT-MMP in
DRM and DSM fractions isolated from cells that were either pretreated or
not with 10 μM U-0126 and, subsequently, stimulated with TNF-α
(10 ng/ml) for 24 h was determined by immunoblotting. Flotillin
2 (FL2) served as a marker of DRM
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increased concentrations of proteases that are directly (MT1-
MMP, CD26 and FAP-α) and indirectly (MMP9 and MMP2)
associated with the cellular membrane in lipid rafts through
activation of the MAPK/ERK signaling pathway. Despite the
notion that the localization and concentration of protease ac-
tivity in the lipid platforms may be crucial for various biolog-
ical processes, including cell migration and invasion, its exact
underlying molecular mechanisms have so far not been fully
elucidated and understood. Further studies may comprehend
this complex process and reveal suitable therapeutic targets.
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